Issues in the design of trials for the evaluation of psychopharmacological treatments for social phobia.
Social phobia was neglected by psychopharmacologically oriented researchers until the past decade. Benefitting from the experience with other anxiety and other affective disorders, however, and also from unique interdisciplinary collaborative arrangements between psychopharmacological and cognitive behavioral investigators, treatment research in social phobia has made remarkable progress in the past few years. Not only has the field itself advanced, but investigative models have been created that are now being adopted and adapted for other disorders.
Liebowitz
M R
MR
Anxiety Disorders Clinic, New York State Psychiatric Institute, New York 10032, USA.
Heimberg
R G
RG
D002986:Clinical Trials as Topic / Q000379:methods*; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010624:Phenelzine / Q000627:therapeutic use; D010698:Phobic Disorders / Q000188:drug therapy*; D012107:Research Design
D008996:Monoamine Oxidase Inhibitors; D010624:Phenelzine